SNYNF supply chain intelligence for Sanofi: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| DBVTF | DBV TECHNOLOGIES | 95% | Reciprocal relationship from DBVTF graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from DBVTF graph: ss, particularly in the engineering and manufacturing of our Viaskin prod… |
| NVAX | Novavax, Inc. | 92% | Reciprocal relationship from NVAX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from NVAX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from NVAX… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 85% | Reciprocal relationship from ARWR graph: nded September 30, 2025. RESULTS OF OPERATIONS The following data summarizes the Company’s results of operations for the following periods indicated: Three Mo… |
| MGNX | MacroGenics, Inc. | 85% | Reciprocal relationship from MGNX graph: IELD in November 2022, and the Company recognized $ million in revenue related to this regulatory milestone during the year ended December 31, 2022. In Novemb… |
| RXRX | Recursion Pharmaceuticals, Inc. | 85% | Reciprocal relationship from RXRX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from RXRX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from RXRX… |
| ACRS | Aclaris Therapeutics, Inc. | 72% | Reciprocal relationship from ACRS graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ACRS graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ACRS… |
| ADAG | Adagene Inc. | 72% | Reciprocal relationship from ADAG graph: age research and all clinical, product development and commercialization activities. Under the Sanofi Agreement, the Group granted Sanofi an exclusive, worldw… |
| ALLR | Allarity Therapeutics, Inc. | 72% | Reciprocal relationship from ALLR graph: ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the… |
| ATOS | Atossa Therapeutics, Inc. | 72% | Reciprocal relationship from ATOS graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ATOS graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ATOS… |
| BLRX | BioLineRx Ltd. | 72% | Reciprocal relationship from BLRX graph: l and the USA. We also claim common law protections for other marks we use in our business. Competitors and other companies could adopt similar marks or try t… |
| CGEN | Compugen Ltd. | 72% | Reciprocal relationship from CGEN graph: res designed to protect against security breaches and other incidents and maintain offsite back-ups of our data, such measures may fail. We maintain periodic … |
| CLDX | Celldex Therapeutics, Inc. | 72% | Reciprocal relationship from CLDX graph: gs; ● restrictions on operations, including costly new manufacturing requirements; or ● seizure or detention of drugs or import bans. The regulatory requireme… |
| CTMX | CytomX Therapeutics, Inc. | 72% | Reciprocal relationship from CTMX graph: tivities and efforts to establish and run clinical trials for CX-2051, CX-904 and CX-801. However, in January 2025, we announced that we would reduce our work… |
| CYTK | Cytokinetics, Incorporated | 72% | Reciprocal relationship from CYTK graph: ging pharmacology could result in an expansion of our business franchise with the development and potential approval of ulacamten for the treatment of a subse… |
| DBVT | DBV Technologies S.A. | 72% | Reciprocal relationship from DBVT graph: the Viaskin patch both biological and chemical substances. Viaskin is a Highly Scalable Manufacturing Technology We currently rely on a single contract manufa… |
| DNLI | Denali Therapeutics Inc. | 72% | Reciprocal relationship from DNLI graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from DNLI graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from DNLI… |
| DRIO | DarioHealth Corp. | 72% | Reciprocal relationship from DRIO graph: panies are true competitors. Traditional Healthcare Systems and Health Plans While many health systems may have their own home-grown solutions for many of the… |
| EDIT | Editas Medicine, Inc. | 72% | Reciprocal relationship from EDIT graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from EDIT graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from EDIT… |
| ELDN | Eledon Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ELDN graph: asures are also imposed by healthcare laws and regulations in international jurisdictions and in those jurisdictions we face the same issues as in the United … |
| EQ | Equillium, Inc. | 72% | Reciprocal relationship from EQ graph: rotagonist Therapeutics, Inc., Sanofi SA, Takeda Pharmaceuticals, Teva Pharmaceuticals, Topas Therapeutics GmbH, and Zedira GmbH. Sales and Marketing Given our … |
| ESPR | Esperion Therapeutics, Inc. | 72% | Reciprocal relationship from ESPR graph: and commercialization objectives. We rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our development… |
| EVAX | Evaxion A/S | 72% | Reciprocal relationship from EVAX graph: drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, there can be considerable pres… |
| FDMT | 4D Molecular Therapeutics, Inc. | 72% | Reciprocal relationship from FDMT graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from FDMT graph: val of a product or impose restrictions on its distribution, such as in the… |
| FULC | Fulcrum Therapeutics, Inc. | 72% | Reciprocal relationship from FULC graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from FULC graph: nce with the agreement, the termination became effective on , which is 120 … |
| GRDX | GridAI Technologies Corp. | 72% | Reciprocal relationship from GRDX graph: parties as set forth in the Rescission Agreement to consummate the transactions contemplated by this Agreement, (ii) the Shareholders shall have delivered a m… |
| HIND | Vyome Holdings, Inc. | 72% | Reciprocal relationship from HIND graph: t such party. Costly and time- consuming litigation could be necessary to enforce and determine the scope of our proprietary rights and failure to obtain or m… |
| IKT | Inhibikase Therapeutics, Inc. | 72% | Reciprocal relationship from IKT graph: tractive; and • a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; if a product candidate obta… |
| IMNM | Immunome, Inc. | 72% | Reciprocal relationship from IMNM graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from IMNM graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from IMNM… |
| IMVT | Immunovant, Inc. | 72% | Reciprocal relationship from IMVT graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from IMVT graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from IMVT… |
| IVF | INVO Fertility, Inc. | 72% | Reciprocal relationship from IVF graph: ls for our product candidates may be larger than it anticipates, enrollment in these clinical trials may be slower than it anticipate or may be lower than it a… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ADAG | Adagene Inc. | 72% | Reciprocal relationship from ADAG graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ADAG graph: age research and all clinical, product development and commercialization ac… |
| ALLR | Allarity Therapeutics, Inc. | 72% | Reciprocal relationship from ALLR graph: ting the need for us to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the… |
| BLRX | BioLineRx Ltd. | 72% | Reciprocal relationship from BLRX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from BLRX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from BLRX… |
| CGEN | Compugen Ltd. | 72% | Reciprocal relationship from CGEN graph: d be leaked or disclosed to others, including if sensitive information is used to train third party AI/ML. Where an AI/ML model ingests sensitive information … |
| CRVS | Corvus Pharmaceuticals, Inc. | 72% | Reciprocal relationship from CRVS graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from CRVS graph: zed clinical trial in order to prioritize the development of our other two … |
| CTMX | CytomX Therapeutics, Inc. | 72% | Reciprocal relationship from CTMX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from CTMX graph: tivities and efforts to establish and run clinical trials for CX-2051, CX-9… |
| CYTK | Cytokinetics, Incorporated | 72% | Reciprocal relationship from CYTK graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from CYTK graph: ging pharmacology could result in an expansion of our business franchise wi… |
| DBVT | DBV Technologies S.A. | 72% | Reciprocal relationship from DBVT graph: the Viaskin patch both biological and chemical substances. Viaskin is a Highly Scalable Manufacturing Technology We currently rely on a single contract manufa… |
| DNLI | Denali Therapeutics Inc. | 72% | Reciprocal relationship from DNLI graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from DNLI graph: entual commercialization of one or more of our product candidates. We expec… |
| DNTH | Dianthus Therapeutics, Inc. | 72% | Reciprocal relationship from DNTH graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from DNTH graph: . Commercial Should any of our product candidates be approved for commercia… |
| DRIO | DarioHealth Corp. | 72% | Reciprocal relationship from DRIO graph: panies are true competitors. Traditional Healthcare Systems and Health Plans While many health systems may have their own home-grown solutions for many of the… |
| EDIT | Editas Medicine, Inc. | 72% | Reciprocal relationship from EDIT graph: ents with third-party manufacturers to obtain finished drug products that are appropriately packaged for sale; • successful development of our internal manufa… |
| ELDN | Eledon Pharmaceuticals, Inc. | 72% | Reciprocal relationship from ELDN graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ELDN graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ELDN… |
| EQ | Equillium, Inc. | 72% | Reciprocal relationship from EQ graph: rotagonist Therapeutics, Inc., Sanofi SA, Takeda Pharmaceuticals, Teva Pharmaceuticals, Topas Therapeutics GmbH, and Zedira GmbH. Sales and Marketing Given our … |
| ESPR | Esperion Therapeutics, Inc. | 72% | Reciprocal relationship from ESPR graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from ESPR graph: se of these systems. Likewise, in the U.S., several states, including Color… |
| EVAX | Evaxion A/S | 72% | Reciprocal relationship from EVAX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from EVAX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from EVAX… |
| FDMT | 4D Molecular Therapeutics, Inc. | 72% | Reciprocal relationship from FDMT graph: val of a product or impose restrictions on its distribution, such as in the form of a REMS. The failure to obtain timely regulatory approval of product candid… |
| GRDX | GridAI Technologies Corp. | 72% | Reciprocal relationship from GRDX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from GRDX graph: s and potential disruption in the operations and business of third-party ve… |
| HIND | Vyome Holdings, Inc. | 72% | Reciprocal relationship from HIND graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from HIND graph: or interference proceedings challenging our patent rights or the patent rig… |
| IKT | Inhibikase Therapeutics, Inc. | 72% | Reciprocal relationship from IKT graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from IKT graph: tractive; and • a product candidate may not be capable of being produced in c… |
| IMNM | Immunome, Inc. | 72% | Reciprocal relationship from IMNM graph: -party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business f… |
| IMVT | Immunovant, Inc. | 72% | Reciprocal relationship from IMVT graph: gulated, unapproved and off-label treatments. Even if a biosimilar product is less effective than our product candidates, a less effective biosimilar may be m… |
| IVF | INVO Fertility, Inc. | 72% | Reciprocal relationship from IVF graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from IVF graph: ls for our product candidates may be larger than it anticipates, enrollment i… |
| JANX | Janux Therapeutics, Inc. | 72% | Reciprocal relationship from JANX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from JANX graph: ach master cell bank is or will be stored in two independent locations, and… |
| KMDA | Kamada Ltd. | 72% | Reciprocal relationship from KMDA graph: lasma suppliers are shut down in response to the number of manufacturers of plasma-based pharmaceuticals decreasing, which may lead to increased prices. We ma… |
| KYMR | Kymera Therapeutics, Inc. | 72% | Reciprocal relationship from KYMR graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from KYMR graph: ch on the targets, and Vertex was responsible for development, manufacturin… |
| MGNX | MacroGenics, Inc. | 72% | Reciprocal relationship from MGNX graph: for these arrangements is either based on an analogy to other accounting literature or an accounting policy election by management. We account for certain com… |
| MGX | Metagenomi Therapeutics, Inc. | 72% | Reciprocal relationship from MGX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from MGX graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from MGX gr… |
| MIRM | Mirum Pharmaceuticals, Inc. | 72% | Reciprocal relationship from MIRM graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from MIRM graph: 808) (“Topic 808”) and determines whether such arrangements involve joint o… |
| MRNA | Moderna, Inc. | 72% | Reciprocal relationship from MRNA graph: at leads to shareholder value, broad eligibility for our equity programs further embeds our "We behave like owners" mindset and helps promote employee retenti… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| SNYNF-DEBT | Debt stack $23.3B | 90% | Market cache reports total debt of $23.3B. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| SNYNF-OWNER-DODGE-COX | Dodge & Cox | 90% | 13F overlay lists Dodge & Cox as top holder; 747 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 100.00 | 2 | |
| CMND | Clearmind Medicine Inc. | 100.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| AUPH | Aurinia Pharmaceuticals Inc. | 100.00 | 2 | |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| CMMB | Chemomab Therapeutics Ltd. | 100.00 | 2 | |
| BDRX | Biodexa Pharmaceuticals Plc | 100.00 | 2 | |
| WHWK | Whitehawk Therapeutics, Inc. | 100.00 | 1 | ['spend'] |
| CLYM | Climb Bio, Inc. | 100.00 | 2 | |
| BORAY | Bora Pharmaceuticals Co., Ltd. | 100.00 | 2 | |
| CPRX | Catalyst Pharmaceuticals, Inc. | 100.00 | 2 | |
| BPTH | Bio-Path Holdings, Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 1 | ['spend'] |
| BLLN | BillionToOne, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 1 | ['spend'] |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 |